Emisphere files second generation IND

Published: 2-Mar-2001


An IND has been filed with the FDA by Emisphere to start human clinical testing of its improved delivery agent for heparin. The agent, coded SNAD, is designed for making orally-available solid dosage formulations of heparin and LMWH.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Read more
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market

Trending Articles

  1. Adragos Pharma acquires Sanofi's Maisons-Alfort sterile fill-finish facility to strengthen European injectables network Global CDMO Adragos Pharma has completed the acquisition of one of Europe's largest sterile injectables manufacturing sites from Sanofi in Maisons-Alfort, France, adding high-volume pre-filled syringe capabilities to its existing fill-finish operations in Switzerland and Livron
  2. Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
  3. FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
  4. Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
  5. Marchesini Group at Interpack 2026 Sustainability, primary packaging, aseptic production, robotics and digital innovation at the heart of this edition

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Analysis

Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem

As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Regulatory

UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead

The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Manufacturing

Labtex - Fresh thinking and innovative solutions

Labtex states: "We are proud to provide unique solutions for laboratories and pilot plants across the UK"
Regulatory

Lonza Nominates Stephen Fry as Independent Board Member

Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Subscribe now